Erythropoietin in cancer-related anemia

Current Opinion in Oncology

Volumn 20, Issue 6, 2008, Pages 685-689

  Fenner, Martin H ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anemia; Cancer; Erythropoietin; Survival; Venous thromboembolism

Indexed keywords

DEXTRAN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRIC GLUCONATE; IRON; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG FORMULATION; ERYTHROPOIESIS; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MORTALITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; HUMANS; IRON; NEOPLASMS; QUALITY OF LIFE; RISK; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOUS THROMBOEMBOLISM;

EID: 55749090066     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283136971     Document Type: Review

References (33)

1. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007; 356:2445-2448.
2. Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol 2008; 9:81.
3. Sacrificing the cash cow. Nat Biotechnol 2007; 25:363.
4. Melosky BL Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol 2008; 15:S10-S15.
5. Rizzo JD, Someffield MR Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26:132-149. The current standard clinical practice guidelines on the use of ESAs in cancer patients.
6. Beutel G, Ganser A. Risks and benefits of erythropoiesie-stimulating agents in cancer management Semin Hematol 2007; 44:157-165.
7. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo controlled study. J Clin Oncol 2008; 26:1040-1050. This randomized trial demonstrated an increased risk of thromboembolism and shorter survival in anemic cancer patients receiving ESA treatment.
8. Gabrilove JL, Ferez EA, Tomita DK, et al. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer 2007; 110:1629-1640.
9. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12:231-242.
10. Hedenus M, Birgegȧrd G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21:627-632.
11. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26:1619-1625.
12. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26:1611-1618. The largest trial comparing intravenous iron to placebo in cancer patients receiving ESAs. Intravenous iron improved the hematologic response rate and reduced the incidence of transfusions.
13. Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008; 26:1579-1581.
14. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369:1502-1504.
15. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43:258-270.
16. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008; 26:592-598.
17. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108: 317-325.
18. Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008; 26:2342-2349.
19. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924. This is the latest and largest meta-analysis of the risks of VTE and mortality associated with ESA treatment.
20. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in nonsmall-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25:1027-1032.
21. Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythro-poietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110:477-488.
22. Agarwal N, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? Facts and fiction - more careful studies are needed. J Clin Oncol 2007; 25:1813-1814.
23. Sinclair AM, Rogers N, Busse L, et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008; 98:1059-1067.
24. Solar P, Feldman L, Jeong JY, et al. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 2008; 122:281-288.
25. Hardee ME, Cao Y, Fu P, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007; 2:e549.
26. Sartelet H, Fabre M, Castaing M, et al. Expression of erythropoietin and its receptor in neuroblastomas. Cancer 2007; 110:1096-1106.
27. Saintigny P, Besse B, Callard P, et al. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I nonsmall cell lung cancer. Clin Cancer Res 2007; 13:4825-4831.
28. Blau CA, Miller CP, Lowe KA, et al. Predictive testing for erythropoietin induced tumor progression in head and neck cancer [abstract no.11007]. J Clin Oncol 2008; 26.
29. Kuykendal A, Bennett CL, McKoy JM, et al. Tumor progression and mortality associated with administration of erythropoiesis stimulating agents (ESAs) to cancer patients: is toxicity due to ESAs or elevated hemoglobin (Hgb) levels? [abstract no.11115]. J Clin Oncol 2008; 26.
30. Mitka M. New limits advised for anemia drugs. JAMA 2008; 299:2016.
31. Tanne JH. FDA committee recommends restricting use of antianaemia drug in cancer. BMJ 2008; 336:632. Report of the most recent ODAC meeting regarding the use of ESAs in cancer patients.
32. http://www.emea.europa.eu/pdfs/human/press/pr/33396308en.pdf, accessed August 14, 2008.
33. http://www.fda.gov/cder/drug/infopage/RHE/default.htm, accessed August 14, 2008.